

December 14, 2021

Michael J. Wagner Esq.
Senior Corporate Counsel
Quest Diagnostics Incorporated
33608 Ortega Highway
San Juan Capistrano, CA 92675

Device: Quest Diagnostics Collection Kit for COVID-19

EUA Number: EUA210497

Company: Quest Diagnostics Nichols Institute (“Quest Diagnostics”)

Indication: For use to collect anterior nares (nasal) swab specimens at-home (which includes in a community- based setting), from individuals age 18 years or older (self-collected), 16 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance) when determined to be appropriate by a healthcare provider, and is intended to be delivered individually or as part of a testing program supported by an entity¹ designated by Quest Diagnostics.

Authorized Laboratories: Testing is limited to laboratories designated by Quest Diagnostics that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meet requirements to perform high complexity tests and that run the specimens collected from the Quest Diagnostics Collection Kit for COVID-19 on an in vitro diagnostic (IVD) molecular test that is indicated for use with the Quest Diagnostics Collection Kit for COVID-19 when used consistent with its authorization.

Dear Mr. Wagner:

On October 8, 2021, based on a request from Quest Diagnostics Infectious Disease, Inc., the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for emergency use of the Quest Diagnostics Collection Kit for COVID-19, pursuant to Section 564

¹ For the purposes of this EUA “entity” refers to any organization that contracts with Quest Diagnostics Incorporated (or a majority owned affiliate) to conduct testing (for example employers who are doing back to work testing, universities, hospitals, healthcare systems, government agencies etc.) that either (1) operates a testing program that includes collection kit supply pick-up locations and specimen drop-off locations overseen by a healthcare provider or (2) requests shipment of collection kits to patients.

of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3) for the indication stated in the letter.²

On November 8, 2021, FDA received a request to further amend the EUA. Based on that request, and having concluded that revising the October 8, 2021, EUA is appropriate to protect the public health or safety under section 564(g)(2)(C) of the Act (21 U.S.C. § 360bbb-3(g)(2)(C)), FDA is reissuing, to you,³ the October 8, 2021, letter in its entirety with the revisions incorporated.⁴ Pursuant to section 564 of the Act and the Scope of Authorization (Section II) and Conditions of Authorization (Section IV) of this reissued letter, your product⁵ is now intended for the indication described above.

On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19.⁶ Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared on March 24, 2020, that circumstances exist justifying the authorization of emergency use of medical devices during the COVID-19 outbreak, subject to the terms of any authorization issued under Section 564(a) of the Act.⁷

FDA considered the totality of scientific information available in authorizing the emergency use of your product for the indication above. A summary of the performance information FDA relied upon is included in the EUA Summary (identified below).

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the

² The Quest Diagnostics Collection Kit for COVID-19 was authorized for use to collect anterior nares (nasal) swab specimens at-home (which includes in a community-based setting), from individuals age 18 years or older (self-collected), 16 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance) when determined to be appropriate by a healthcare provider, and is intended to be delivered individually or as part of a testing program supported by an entity designated by Quest Diagnostics. Testing was limited to laboratories designated by Quest Diagnostics that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meet requirements to perform high complexity tests and that run the specimens collected from the Quest Diagnostics Collection Kit for COVID-19 on an in vitro diagnostic (IVD) molecular test that is indicated for use with the Quest Diagnostics Collection Kit for COVID-19 when used consistent with its authorization.

³ For ease of reference, this letter will use the term “you” and related terms to refer to Quest Diagnostics Nichols Institute (“Quest Diagnostics”), a subsidiary of Quest Diagnostics Incorporated.

⁴ The revisions to the October 8, 2021, letter and authorized labeling are to update the EUA holder name from Quest Diagnostics Infectious Disease, Inc. to Quest Diagnostics Nichols Institute and make some minor clarifying updates to the EUA Summary.

⁵ For ease of reference, this letter will use the term “your product” to refer to the Quest Diagnostics Collection Kit for COVID-19 used for the indication identified above.

⁶ U.S. Department of Health and Human Services, *Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act*, 21 U.S.C. § 360bbb-3. 85 FR 7316 (February 7, 2020).

⁷ U.S. Department of Health and Human Services, *Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act*, 21 U.S.C. § 360bbb-3. 85 FR 17335 (March 27, 2020).

Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that:

1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus;
2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19 by serving as an appropriate means to collect and transport human specimens so that an authorized laboratory can detect SARS-CoV-2 RNA from the collected human specimen, and that the known and potential benefits of your product when used for such use, outweigh the known and potential risks of your product; and
3. There is no adequate, approved, and available alternative to the emergency use of your product.⁸

II. Scope of Authorization

I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.

Authorized Product Details

Your product is a collection kit intended for use to collect anterior nares (nasal) swab specimens at-home (which includes in a community- based setting), from individuals age 18 years or older (self-collected), 16 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance) when determined to be appropriate by a healthcare provider. Your product is intended to be delivered individually or as part of a testing program supported by an entity designated by Quest Diagnostics.

Your product is available via four different workflows: Bulk, Bulk&Activate, Individual, and Individual&Activate. In the Bulk and Bulk&Activate an entity, that is designated by Quest Diagnostics, operates a testing program that includes collection kit supply pick-up locations and specimen drop-off locations overseen by a healthcare provider. Bulk collection kit supplies for your product are sent to the designated entity where they are assembled and distributed to patients/adult caregiver, when determined to be appropriate by a healthcare provider, at the pick-up location by trained front-line staff. Individuals then collect the specimen according to the provided authorized sample collection instructions (summarized in the authorized labeling) and return the specimen to trained front-line staff at the drop-off location, according to the specimen return instructions. Once the specimens are accepted by the drop-off location, arrangements are made to have them transferred to a laboratory designated by Quest Diagnostics that are certified

⁸ No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the Act.

under CLIA, and that meet requirements to perform high complexity tests, for COVID-19 testing. In the Individual and Individual&Activate workflows, a healthcare provider orders patient testing, then a pre-assembled Quest Diagnostics Collection Kit for COVID-19 is shipped to the patient/adult caregiver. The individual then collects the specimen according to the provided authorized sample collection instructions (summarized in the authorized labeling) and returns it via the shipping instructions using the pre-paid shipping materials included in the kit back to a laboratory designated by Quest Diagnostics, that are certified under CLIA, and that meet requirements to perform high complexity tests, for COVID-19 testing. Nasal swab specimens collected using your product are transported at ambient temperature, and for all workflows, once the patient specimen is received at the laboratory it is accessioned according to your products’ authorized accessioning standard operating procedure (see authorized labeling below) and tested using a IVD test for the detection of SARS-CoV-2 RNA that is indicated for use with your product before the results are electronically reported to the ordering healthcare provider and patient/adult caregiver.

The Quest Diagnostics Collection Kit for COVID-19 includes the following materials or other authorized materials (as may be requested under Condition S. below) depending on the workflow:

- Bulk and Bulk&Activate Workflows:** Basic kit supplies that include individually wrapped swabs, specimen transport tubes containing liquid media and zip-lock bags containing a desiccant are shipped to the entity designated by Quest Diagnostics, either as bulk supply materials or in convenience packs. Using these supplies the Entity’s trained front-line staff then provides the patient/adult caregiver with the following materials at the supply pick-up location:

Sample Collection Instructions
Swab – individually wrapped
Specimen Transport Tube - containing 2 mL or 3 mL of liquid – tube either with unique barcode label (Bulk&Activate) or without (Bulk)
Zip-lock bag (biohazard symbol) and desiccant
Test Requisition (pre-printed) (Bulk) or Activation Card (Bulk&Activate)
Entity specific Specimen Return Instructions – at Drop-off Location
Pre-printed tube label (Bulk)

- Individual and Individual&Activate Workflows:** Your product is pre-assembled and include the following:

Sample Collection Instructions that include Shipping Instructions
Swab– individually wrapped
Specimen Transport Tube - containing 2 mL or 3 mL of liquid – tube either with unique barcode label (Individual&Activate) or without (Individual)
Zip-lock bag (biohazard symbol) and desiccant
Test Requisition (pre-printed) (Individual) or Activation Card

(Individual&Activate)
Shipping box and return bag with a UN3373 symbol with pre-paid return shipping label
Priority label (optional)
Pre-printed tube label (Individual)

The Bulk&Activate and Individual&Activate workflows allow the patient/adult caregiver to activate the collection materials online via Quest Activate webpage (<https://activate.questdiagnostics.com/>) using the Activation Card (provided with your product). Alternatively, the Bulk and Individual workflows allow the patient/ adult caregiver to manually provide specific information by completing the test requisition form included in the kit.

The labeling entitled “Quest Diagnostics Collection Kit for COVID-19 (Individual),” “Quest Diagnostics Collection Kit for COVID-19 (Individual&Activate),” Quest Diagnostics Collection Kit for COVID-19 (Bulk),” Quest Diagnostics Collection Kit for COVID-19 (Bulk&Activate),” the EUA Summary (available at <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas>), the following standard operating procedure (SOP): “Unobserved Collected Sample Processing for COVID-19 Molecular Testing” Non-Technical SOP, and the documents provided to authorized entities using the Bulk and Bulk&Activate workflows as part of the contract provisions⁹ is required to be made available as set forth in the Conditions of Authorization (Section IV), and are collectively referred to as “authorized labeling.”

The above described product, when accompanied by the authorized labeling as set forth in the Conditions of Authorization (Section IV) is authorized to be distributed and used under this EUA, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

I have concluded, pursuant to Section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of your product, when used consistent with the Scope of Authorization of this letter (Section II), outweigh the known and potential risks of your product.

I have concluded, pursuant to Section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that your product may be effective in diagnosing COVID-19 by serving as an appropriate means to collect and transport human specimens so that an authorized laboratory can detect SARS-CoV-2 RNA from the collected human specimen when used consistent with the Scope of Authorization of this letter (Section II), pursuant to Section 564(c)(2)(A) of the Act.

FDA has reviewed the scientific information available to FDA, including the information

⁹ Documents provided by Quest Diagnostics to authorized entities they designate to use the Bulk and Bulk&Activate workflows for the Quest Diagnostics Collection Kit for COVID-19, included as part of the contract provisions (described in footnote 1), include: “Quest Diagnostics Collection Kit for COVID-19 (Bulk and Bulk&Activate Workflows) Instructions for Use For Front-line Staff,” “Information for Providing Collection Materials to Patients (Bulk),” “Specimen Return Instructions (Bulk),” “Information for Accepting Specimens (Bulk),” “Information for Providing Collection Materials to Patients (Bulk&Activate),” “Specimen Return Instructions (Bulk&Activate),” and “Information for Accepting Specimens (Bulk&Activate).”

supporting the conclusions described in Section I above, and concludes that your product (as described in the Scope of Authorization of this letter (Section II)) meets the criteria set forth in Section 564(c) of the Act concerning safety and potential effectiveness.

The emergency use of your product under this EUA must be consistent with, and may not exceed, the terms of this letter, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section IV). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the Act described above and the Secretary of HHS's corresponding declaration under Section 564(b)(1) of the Act, your product is authorized for the indication above.

III. Waiver of Certain Requirements

I am waiving the following requirements for your product during the duration of this EUA:

- Current good manufacturing practice requirements, including the quality system requirements under 21 CFR Part 820 with respect to the design, manufacture, packaging, labeling, storage, and distribution of your product, but excluding Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I (Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).

IV. Conditions of Authorization

Pursuant to Section 564(e) of the Act, I am establishing the following conditions on this authorization:

Quest Diagnostics (You) and Authorized Distributor(s)¹⁰

- A. Your product must comply with the following labeling requirements under FDA regulations: the intended use statement (21 CFR 809.10(a)(2), (b)(2)); adequate directions for use (21 U.S.C. 352(f)), (21 CFR 809.10(b)(5), (7), and (8)); appropriate limitations on the use of the device including information required under 21 CFR 809.10(a)(4); and any available information regarding performance of the device, including requirements under 21 CFR 809.10(b)(12).
- B. You and authorized distributor(s) must make available all instructions related to the collection of anterior nasal swab specimens (i.e., the Quest Diagnostics Collection Kit for COVID-19 (Individual) and/or the Quest Diagnostics Collection Kit for COVID-19 (Individual & Activate)) in the shipped kit and make available all instructions on your website(s).
- C. You and authorized distributor(s) must make available to authorized entities using the bulk workflows for the Quest Diagnostics Collection Kit for COVID-19 all instructions

¹⁰ “Authorized Distributor(s)” are identified by you, Quest Diagnostics, in your EUA submission as an entity allowed to distribute the Quest Diagnostics Collection Kit for COVID-19.

related to the collection of anterior nasal swab specimens (i.e., the Quest Diagnostics Collection Kit for COVID-19 (Bulk) and/or the Quest Diagnostics Collection Kit for COVID-19 (Bulk & Activate)) either electronically for bulk supplies or packaged within the convenience packs kit and make available all instructions on your website(s).

- D. You and authorized distributor(s) must inform authorized laboratories, authorized entities and relevant public health authorities of this EUA, including the terms and conditions herein, and any updates made to your product, or the authorized labeling.
- E. Through a process of inventory control, you and authorized distributor(s) must maintain records of the numbers and locations to which your product is distributed.
- F. You and authorized distributor(s) must maintain customer complaint files on record. You will report to FDA any significant complaints about usability or deviations from the established performance characteristics of the product of which you become aware.
- G. You and authorized distributor(s) are authorized to make available additional information relating to the emergency use of your product that is consistent with, and does not exceed, the terms of this letter of authorization.
- H. You and authorized distributors must have lot release procedures and the lot release procedures, including the study design and statistical power, must ensure that the tests released for distribution have the performance claimed in the authorized labeling.
- I. If requested by FDA, you and authorized distributors must submit lot release procedures to FDA, including sampling protocols, testing protocols, and acceptance criteria, that you use to release lots of the Quest Diagnostics Collection Kit for COVID-19 for distribution in the U.S. If such lot release procedures are requested by FDA, you must provide it within 48 hours of the request.
- J. You must comply with the following requirements under FDA regulations: 21 CFR 820 Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I (Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).

Quest Diagnostics (You)

- K. You must notify FDA of any authorized distributor(s) of your product, including the name, address, and phone number of any authorized distributor(s).
- L. You must notify FDA of any authorized laboratories designated by Quest Diagnostics to use your product, including the name, address, and phone number of any authorized laboratories.

- M. You must keep records of any authorized entities designated by Quest Diagnostics to use the Bulk and Bulk&Activate workflows for your product and must make such records available to FDA within 5 business days for inspection upon request.
- N. You must have a process in place to designate authorized entities to use the Bulk and Bulk&Activate versions of your product that ensures the use of your product by the authorized entity under this EUA is consistent with, and may not exceed, the terms of this letter, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section IV).
- O. You will require that entities using the Quest Diagnostics collection Kit for COVID-19 acknowledge receipt of the following disclosure "*Specimens that are collected using the Quest Diagnostics Collection Kit for COVID-19 were not tested with an internal control to confirm that the specimen was properly collected. As such, unobserved collected specimens using the Quest Diagnostics Collection Kit for COVID-19 from SARS-CoV-2 positive individuals may yield negative results if the specimen was not collected properly*" that authorized laboratories must also include in test reports as required by Condition Z. below.
- P. You must provide authorized distributor(s), authorized entities and authorized laboratories with a copy of this EUA and communicate any subsequent revisions that might be made to this EUA and its authorized accompanying materials.
- Q. You must provide authorized laboratories with a copy of the “Unobserved Collected Sample Processing for COVID-19 Molecular Testing” Non-Technical Standard Operating Procedure (SOP).
- R. You must provide authorized entities using the Bulk and Bulk&Activate versions of your product with copies of the authorized labeling (described in footnote 9) included as part of the contract provisions in the signed customer service agreement (described in footnote 1).
- S. You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling. Any requests for changes to this EUA should be submitted to the Division of Microbiology (DMD)/Office of Health Technology 7 (OHT7)-Office of In Vitro Diagnostics and Radiological Health (OIR)/Office of Product Evaluation and Quality (OPEQ)/Center for Devices and Radiological Health (CDRH) and require appropriate authorization from FDA prior to implementation.
- T. You must have a process in place to track adverse events associated with the Quest Diagnostics Collection Kit for COVID-19, including any occurrences of false results with your product, and report any such events to FDA pursuant to 21 CFR Part 803. Serious adverse events, especially unexpected biosafety concerns, should immediately be reported to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUAReporting@fda.hhs.gov).

- U. You must submit to FDA a summary report summarizing the results of testing performed using anterior nasal swab specimens collected with the Quest Diagnostics Collection Kit for COVID-19 using the reporting parameters agreed upon by FDA to sufficiently assess updates made to the Quest Diagnostics Collection Kit for COVID-19. The summary report should be stratified by age group and kit option (Individual, Individual&Activate, Bulk and Bulk&Activate) including how many kits were requested and sent for specimen collection to individuals, how many kits were distributed and returned according to the instructions, how many specimens had to be rejected during accession and the main reasons for rejection, and the positivity rate.

Authorized Entities

- V. Authorized entities using the Bulk and Bulk&Activate Options for your product must have processes in place and oversee use of your product to ensure that your product is used as outlined in the authorized labeling and in the entity’s signed customer service agreement with Quest Diagnostics.
- W. Authorized entities must report significant customer complaints about the usability of your product of which they become aware to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and you (michael.j.wagner@questdiagnostics.com).

Authorized Laboratories

- X. Authorized laboratories testing anterior nasal swab specimens collected using your product must follow the “Unobserved Collected Sample Processing for COVID-19 Molecular Testing” Non-Technical Standard Operating Procedure (SOP) when accepting specimens for testing.
- Y. Authorized laboratories using your product must use it only in conjunction with COVID-19 in vitro diagnostic (IVD) molecular tests that are indicated for use with your product.
- Z. Authorized laboratories testing authorized specimens collected using your product must include in the test report the following limitation: *“Specimens that are collected using the Quest Diagnostics Collection Kit for COVID-19 were not tested with an internal control to confirm that the specimen was properly collected. As such, unobserved collected specimens using the Quest Diagnostics Collection Kit for COVID-19 from SARS-CoV-2 positive individuals may yield negative results if the specimen was not collected properly.”*
- AA. Authorized laboratories must collect information on the performance of your product and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and you (michael.j.wagner@questdiagnostics.com) any suspected occurrence of false positive or false negative results and significant deviations

from the established performance characteristics of your product of which they become aware.

Quest Diagnostics (You), Authorized Distributor(s), Authorized Entities and Authorized Laboratories

BB. You, authorized distributor(s), authorized entities and authorized laboratories using your product must ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

Conditions Related to Printed Materials, Advertising and Promotion

CC. All descriptive printed matter, advertising, and promotional materials relating to the use of your product shall be consistent with the authorized labeling, as well as the terms set forth in this EUA and the requirements set forth in section 502(a), (q)(1), and (r) of the Act, as applicable, and FDA implementing regulations.

DD. No descriptive printed matter, advertising, or promotional materials relating to the use of your product may represent or suggest that this test is safe or effective for the detection of SARS-CoV-2.

EE. All descriptive printed matter, advertising, and promotional materials (with the exception of the “Activation Card” and generic sections of the patient portal associated with the Activate workflows) relating to the use of your product shall clearly and conspicuously state that:

- This product has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA;
- This product has been authorized only for the collection and maintenance of anterior nasal swab specimens as an aid in detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of medical devices under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The emergency use of your product as described in this letter of authorization must comply with the conditions and all other terms of this authorization.

V. Duration of Authorization

This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of medical devices during the COVID-19 outbreak is terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act.

Sincerely,

Jacqueline A. O’Shaughnessy, Ph.D.
Acting Chief Scientist
Food and Drug Administration

Enclosure